Community/Retail

Whether it be delivery options, remote pharmacy, increasing roles for pharmacists and technicians, or fluctuating patient volume, the impact of COVID-19 can be felt in community pharmacies across the United States.

Critically ill patients admitted to the intensive care unit (ICU) with coronavirus disease 2019 (COVID-19) are 10 times more likely to develop cardiac arrhythmias.

In addition to finding that depression affects up to 70% of women transitioning into menopause, investigators have also identified the greatest risk factors.

Pharmacy Times® interviewed Tim Safley and Jon Pritchett of ACHC on evaluating the opportunities for long-term care (LTC) pharmacies in relation to specialty pharmacy accreditation.

In addition to allopathic or prescription medications to manage depression stemming from this pandemic, there are integrative medicines, as well as health and wellness modalities, that can be used to improve mental health.

The diagnosis and treatment of attention deficit hyperactivity disorder (ADHD) in children and teens can be a complex and unique challenge for providers.

Pharmacy Times spoke with George Van Antwerp, MBA, managing director of Deloitte, about where he sees the pharmacy field going in the next 20 years.

When taken daily, PrEP is highly effective for preventing HIV from sex or injection drug use.

Multiple pharmacies recently received letters from ESI stating that on behalf of TRICARE and the Defense Health Agency, ESI was recouping money for compound drug claims submitted in 2015.

Current guidelines for PPE in the general care of patients with coronavirus disease 2019 (COVID-19) in acute care facilities recommend gloves, an isolation gown, eye protection, and a medical mask or N95 respirator.

COVID-19 increases the risk of blood clotting due to increased activity in blood clotting cells.

Household cleaning and disinfectant use has increased in homes as a result of the coronavirus disease 2019 (COVID-19) pandemic.

Pharmacy Times® interviewed Samir Balile, PharmD, on the safety measures Giant pharmacies are taking to protect patients and staff members upon reopening their doors, as well as the importance of the flu vaccine during COVID-19.

Results from 2 initial phase 3 studies evaluating an investigational 15-valent pneumococcal conjugate vaccine were recently released, assessing its immunogenicity, safety, and tolerability.

The Pharmacy Health Information Collaborative is currently accepting comments from stakeholders.

According to a recent study published in Gut, inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn disease, is associated with a more than doubled likelihood of developing dementia.

FDA guidance encourages diverse study pools at all phases of development.

A statewide Indiana study shows that 47% of people are using technology to communicate with their health care providers, and less than a quarter are having conversations with their providers about using health information technology (HIT).

Women are more likely to receive multiple opioid prescriptions, study finds.

New research indicates that even with effective antiretroviral treatment, HIV may still affect the central nervous system.

The findings include airway inflammation and rapid development of pulmonary edema, coronary artery aneurysms, and extensive intra-abdominal inflammatory changes, according to the study authors.

Collaboration between pharmacists and general practice teams improves patient care and increases savings.

A new heart valve combines the biocompatibility of a biological valve with the robustness of a mechanical one.

Remdesivir, the investigational drug for the treatment of the coronavirus disease 2019 (COVID-19), will be sold for $390 per vial.

Some states are implementing laws that are allowing pharmacists to expand their roles temporarily, but these laws vary by state and there is no uniformity in what all pharmacists can do during this time.

COVID-19 attacks the cardiovascular system and may exasperate preexisting heart conditions.

Current research has already found that CVD is among the most common pre-existing conditions among people who die from COVID-19.

The paper is an update to previous guidelines released by ACSM and the American Heart Association in 1998.

Studying blood samples from critically ill patients at the London Health Sciences Center (LHSC), the researchers identified a unique pattern of 6 molecules that could be used as therapeutic targets to treat the virus, as reported in the Critical Care Explorations journal.

The measles, mumps, and rubella vaccine may hold the key to the mystery surrounding children and the COVID-19 pandemic.